# Junta clínica — PT-pseudo_7bcbfa157137 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_7bcbfa157137",
  "pid": "PT-pseudo_7bcbfa157137",
  "task": 1,
  "psa": 7.4,
  "age": 69,
  "months": 1,
  "pirads": "4",
  "psad": 0.117,
  "psav": 1.55,
  "psap": 5.7,
  "vol": 63.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.83814454,
  "medhx": "Hypertension, Type 2 diabetes",
  "meds": "valsartan, lisinopril, metoprolol, metformin, empagliflozin",
  "notes": "PSA 7.4 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 63 mL. csPCa 0.84.",
  "pmhx": [
    "Hypertension",
    "Type 2 diabetes"
  ],
  "allergies": [],
  "vitals": {
    "weight": "89 kg",
    "height": "186 cm",
    "bmi": "25.7",
    "bp": "124/77 mmHg",
    "hr": "69 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested due to previous biopsy positivity alongside a continuous upward trend in PSA levels."
    },
    {
      "s": "History",
      "t": "This 69-year-old gentleman, married and residing with his partner, has recently stepped down from his role as a postal worker. He abstains from tobacco, walks approximately 45 minutes daily, and consumes around 13 units of alcohol weekly. His medical background includes hypertension and type 2 diabetes, currently regulated by valsartan, lisinopril, metoprolol, metformin, and empagliflozin, with recent cardiology parameters remaining stable. Urinary symptoms are negligible, reflected by an IPSS score of 1. Past surgical history encompasses a knee arthroscopy performed half a decade ago, and he occasionally experiences minor lower back stiffness following extended gardening, neither requiring specialist care. He previously opted out of research trials. Adenocarcinoma was confirmed on his earlier biopsy. He maintains full independence in daily activities and remains in good overall health."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Examination is normal; the prostate exhibits a symmetrically enlarged contour with a smooth, firm texture, devoid of palpable asymmetry or discrete nodules. General assessment shows no abnormalities. Blood pressure registers at 124/77 mmHg, accompanied by a regular cardiac rhythm of 69 bpm. Abdominal palpation yields a soft, non-tender abdomen free of palpable masses or organ enlargement."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [],
  "alcohol": "13 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_7bcbfa157137
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 69-year-old male
  - PSA: 7.4 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.117 ng/mL²
  - PSA velocity: 1.55 ng/mL/yr
  - Prior PSA: 5.7 ng/mL
  - Prostate volume: 63.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.83814454 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Type 2 diabetes
  - Problem list / PMHx: Hypertension, Type 2 diabetes
  - Current medication: valsartan, lisinopril, metoprolol, metformin, empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 7.4 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 63 mL. csPCa 0.84.

Vitals: weight 89 kg, height 186 cm, BMI 25.7, BP 124/77 mmHg, HR 69 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested due to previous biopsy positivity alongside a continuous upward trend in PSA levels.

History: This 69-year-old gentleman, married and residing with his partner, has recently stepped down from his role as a postal worker. He abstains from tobacco, walks approximately 45 minutes daily, and consumes around 13 units of alcohol weekly. His medical background includes hypertension and type 2 diabetes, currently regulated by valsartan, lisinopril, metoprolol, metformin, and empagliflozin, with recent cardiology parameters remaining stable. Urinary symptoms are negligible, reflected by an IPSS score of 1. Past surgical history encompasses a knee arthroscopy performed half a decade ago, and he occasionally experiences minor lower back stiffness following extended gardening, neither requiring specialist care. He previously opted out of research trials. Adenocarcinoma was confirmed on his earlier biopsy. He maintains full independence in daily activities and remains in good overall health.

Physical examination: DRE: Examination is normal; the prostate exhibits a symmetrically enlarged contour with a smooth, firm texture, devoid of palpable asymmetry or discrete nodules. General assessment shows no abnormalities. Blood pressure registers at 124/77 mmHg, accompanied by a regular cardiac rhythm of 69 bpm. Abdominal palpation yields a soft, non-tender abdomen free of palpable masses or organ enlargement.

Patient info: retired postal worker; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 13 units / week; exercise Walking 45 min/day; IPSS score: 1/35 (mild LUTS).


Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.12 epistemic (95% band 0.23-0.70); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 69 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 7.4 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 63 mL (1% of my signal; from log_vol, vol) · PSA density = 0.117 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.84 (1% of my signal; from cspca) · PI-RADS = 4 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 69 · DRE = Normal · PSA = 7.4 ng/mL · prostate volume = 63 mL · PSA density = 0.117 · PI-RADS = 4 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.75: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  2. distance 0.78: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."
  3. distance 0.86: PI-RADS 4, PSA 4.5, PSAD 0.07, age 71, DRE Normal -> DEFER (clear). He wrote: "Man on active surveillance. MRI stabile and PSA moderately high."

PRECEDENT: DEFER (weighted vote 0.35 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · age = 69 · PI-RADS = 4
  noted      family history = not opened (0 of 91) · DRE = Normal · PSA = 7.4 ng/mL · prostate volume = 63 mL · PSA density = 0.117 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 69 · PSA = 7.4 ng/mL · PI-RADS = 4
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 63 mL · PSA density = 0.117 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using PI-RADS thresholds to guide biopsy decisions, noting that a threshold of PI-RADS $\ge 3$ is used to trigger biopsy, and that increasing the threshold to $\ge 4$ could avoid a significant number of biopsies while missing some cancer.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your variable 'prior biopsy = Positive' is marked decisive, whereas the guideline treats this as context, and the guideline suggests the decision relies on PI-RADS thresholds. The guideline suggests that for a patient with a PI-RADS 4 lesion, the decision should be guided by the risk-adapted matrix table, which is not represented by your variable. The guideline requires the prior grade of the prior biopsy to settle the decision, which is a fact the panel does not represent.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: a rising PSA velocity is a factor that the guideline considers in risk stratification.
laboratory_results - the PSA density: the PSA density is a factor in the risk-adapted matrix table that the guideline uses to guide the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the documented grade of the prior biopsy and the PSA trend to guide the decision.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
  psa_trend (get_psa_trend) -> Does the PSA velocity inform the risk stratification?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy, the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> Does the PSA density factor into the risk-adapted matrix table for the decision?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?
  Q2. What is the PSA velocity?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Center: Antoni van Leeuwenhoek | Study: Multiparametric MRI of the Prostate | Date: 28 Jan 2025. Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision? The report states: "T2-weighted sequences reveal a 14 mm hypointense focus within the right peripheral zone at the mid-gland level. There is no evidence of extraprostatic extension, seminal vesicle invasion, suspicious lymphadenopathy, or osseous abnormalities."

psa_trend
Does the PSA velocity inform the risk stratification? The PSA velocity shows a rise from 2.2 ng/mL in Feb 2022 to 7.4 ng/mL in Jan 2025.

previous_notes
What is the documented grade of the prior biopsy, the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due? The notes state: "A transrectal ultrasound-guided biopsy conducted earlier this year returned positive histological results."

laboratory_results
Does the PSA density factor into the risk-adapted matrix table for the decision? The laboratory results show: "Free PSA 2.05 ng/mL, %Free PSA 28%".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already established the prior biopsy status, and the other documents provided the necessary clinical and imaging context.

WHAT THIS SUPPORTS
FOR sampling this patient now
The previous notes document a "positive histological results" from a prior biopsy.
The PSA trend shows a significant rise, moving from 2.2 ng/mL to 7.4 ng/mL over three years.

AGAINST sampling this patient now
The DRE is reported as "Normal" on the physical examination.
The mpMRI shows a PI-RADS 4 lesion, which is concerning but not definitive for immediate action alone.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 7.40 ng/mL over 4 points spanning 35 months; velocity +2.00 ng/mL per year; doubling time about 18 months.
PROJECTION at 6 months: 8.8 ng/mL, conformal 95% band 2.5-30.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 7.4 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: uncertain — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.65
  uncertainty  +/- 0.12 epistemic (95% band 0.42-0.89), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 4 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Normal (5% of my signal; from dre_suspicious) · PSA = 7.4 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 63 mL (4% of my signal; from log_vol, vol) · PSA density = 0.117 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.47  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.65  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.35  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.61 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          69                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psa          7.4 ng/mL                    E1:not E3:not cohort:not library:not E2:not          -> important
  vol          63 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.117                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.84                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       4                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: borderline.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened appear to answer the moderator's questions. The `previous_notes` state a "positive histological results" from a prior biopsy, and the `psa_trend` shows a rise from 2.2 ng/mL to 7.4 ng/mL.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of BIOPSY, as the previous notes document a prior positive biopsy, which is a key factor the guideline emphasizes.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? The `previous_notes` state "positive histological results," but the specific grade (ISUP) is not explicitly stated, which is a gap. Q2. What is the PSA velocity? The `psa_trend` answers this, showing a rise of 2.00 ng/mL per year.

WHAT CARRIES WEIGHT, AND WHY
prior biopsy: Positive (decisive) because the previous notes document a positive histological result, which is a factor the guideline requires. PSA velocity: noted because the trend shows a significant rise from 2.2 ng/mL to 7.4 ng/mL over three years. I agree with the PANEL-PROTOCOL's weighting of these factors. My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the documented prior positive biopsy, combined with the rising PSA velocity, aligns with the guideline's indication for further tissue sampling.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

69y male, PSA 7.4, PI-RADS 4, prior positive biopsy grade unrecorded. Rising PSA velocity and unrecorded prior grade suggest sampling is warranted to determine management. The lack of prior grade is the key factor pushing for biopsy over surveillance.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
